Urofollitropin API: The Essential Intermediate for Ovarian Stimulation

Urofollitropin, a highly purified urinary-derived follicle‑stimulating hormone (FSH), is one of the most widely used active pharmaceutical ingredients in fertility treatments.

The value of urofollitropin lies in its ability to provide consistent FSH activity with minimal luteinizing hormone (LH) contamination. Unlike recombinant FSH, urinary‑derived urofollitropin retains the natural glycosylation pattern and has a well‑established safety record spanning over four decades.

From a supply chain perspective, urofollitropin intermediates offer several advantages. They are more cost‑effective than recombinant alternatives, making them the preferred choice for generic fertility drugs in emerging markets. Furthermore, urinary sourcing does not depend on complex cell culture facilities, ensuring a more resilient supply during global disruptions.